Table 2 Secondary efficacy variables at 3 weeks in lanicemine 100 mg, lanicemine 150 mg and placebo groups (ITT, LOCF) (phase IIB study, study 9)

From: Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

Efficacy variable

Lanicemine (100 mg) (n=51)

Lanicemine (150 mg) (n=51)

Placebo (n=50)

Response,a n (%)

19 (37)

15 (29)

8 (16)

(OR vs placebo)

OR=3.34

OR=2.12

 

P-value

P=0.014

P=0.137

 

Remission,b n (%)

10 (20)

11 (22)

5 (10)

(OR vs placebo)

OR=2.20

OR=2.36

 

P-value

P=0.186

P=0.144

 

CGI-I, n (%), category ⩽2

32 (65)

24 (47)

13 (26)

(OR vs placebo)

OR=5.41

OR=2.54

 

P-value

P=<0.001

P=0.030

 

CGI-S score vs baseline

–1.5

−1.5

−0.8

(Δ vs placebo)

Δ=−0.7

Δ=−0.6

 

P value

P=0.006

P=0.009

 

QIDS-SR-16 score vs baseline

−8.7

−6.8

−6.3

(Δ vs placebo)

Δ=−2.5

Δ=−0.6

 

P-value

P=0.016

P=0.575

 

HAM-D-17 score vs baseline

−11.9

−10.7

−8.0

(Δ vs placebo)

Δ=−3.8

Δ=−2.6

 

P-value

P=0.010

P=0.079

 

HAM-A score vs baseline

−7.8

−7.2

−4.2

(Δ vs placebo)

Δ=−3.5

Δ=−3.0

 

P-value

P=0.002

P=0.009

 

Q-LES-Q-SF score vs baseline

8.1

6.8

4.2

(Δ vs placebo)

Δ=3.9

Δ=2.6

 

P-value

P=0.026

P=0.137

 
  1. Abbreviations: OR, odds ratio; CGI-I, Clinical Global Impression of Improvement; CGI-S, Clinical Global Impression of Severity; HAM-D, Hamilton Rating Scale for Depression; HAM-A, Hamilton Rating Scale for Anxiety; ITT, intent-to-treat; LOCF, last observation carried forward; MADRS, Montgomery Åsberg Depression Rating Scale; QIDS-SR-16, Quick Inventory of Depressive Symptomatology-Self-Report; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form.
  2. P values: vs placebo.
  3. aResponse defined as ⩾50% reduction from baseline in MADRS total score at week 3.
  4. bRemission defined as MADRS total score ⩽10 at week 3.
Back to article page